Glycan-based biomarkers for mucopolysaccharidoses.

[1]  C. Hendriksz,et al.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. , 2013, Molecular genetics and metabolism.

[2]  L. Ijlst,et al.  Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease , 2013, Journal of Inherited Metabolic Disease.

[3]  L. Ijlst,et al.  Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. , 2012, Molecular genetics and metabolism.

[4]  J. Esko,et al.  A Genetic Model of Substrate Reduction Therapy for Mucopolysaccharidosis* , 2012, The Journal of Biological Chemistry.

[5]  Pauline M Rudd,et al.  Glycans as cancer biomarkers. , 2012, Biochimica et biophysica acta.

[6]  Jian Liu,et al.  Deciphering Mode of Action of Heparanase Using Structurally Defined Oligosaccharides* , 2012, The Journal of Biological Chemistry.

[7]  R. Giugliani,et al.  Biomarkers for the mucopolysaccharidoses: discovery and clinical utility. , 2012, Molecular genetics and metabolism.

[8]  R. D'Hooge,et al.  Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice , 2012, Proceedings of the National Academy of Sciences.

[9]  P. Dickson,et al.  Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I. , 2012, Molecular genetics and metabolism.

[10]  S. Stockler,et al.  Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients , 2012, Journal of Inherited Metabolic Disease.

[11]  T. Lehman,et al.  Diagnosis of the mucopolysaccharidoses. , 2011, Rheumatology.

[12]  J. Muenzer.  Overview of the mucopolysaccharidoses. , 2011, Rheumatology.

[13]  V. Valayannopoulos,et al.  Therapy for the mucopolysaccharidoses. , 2011, Rheumatology.

[14]  J. Esko,et al.  Disease-Specific Non-Reducing End Carbohydrate Biomarkers for Mucopolysaccharidoses , 2011, Nature chemical biology.

[15]  G. Węgrzyn,et al.  Substrate reduction therapies for mucopolysaccharidoses. , 2011, Current pharmaceutical biotechnology.

[16]  R. Furneaux,et al.  Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. , 2011, Bioanalysis.

[17]  J. Leary,et al.  Mucopolysaccharidosis Type I, Unique Structure of Accumulated Heparan Sulfate and Increased N-Sulfotransferase Activity in Mice Lacking α-l-iduronidase* , 2011, The Journal of Biological Chemistry.

[18]  D. Pan.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses. , 2011, Current pharmaceutical biotechnology.

[19]  F. Wijburg,et al.  Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. , 2011, Current Pharmaceutical Biotechnology.

[20]  J. Leary,et al.  A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. , 2011, Analytical chemistry.

[21]  G. A. van der Marel,et al.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies , 2011, Journal of Inherited Metabolic Disease.

[22]  Yasuyuki Suzuki,et al.  Comparison of Liquid Chromatography–Tandem Mass Spectrometry and Sandwich ELISA for Determination of Keratan Sulfate in Plasma and Urine , 2011, Biomarker insights.

[23]  J. Esko,et al.  Secondary Storage of Dermatan Sulfate in Sanfilippo Disease* , 2010, The Journal of Biological Chemistry.

[24]  J. Petty,et al.  Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases , 2010, Journal of Inherited Metabolic Disease.

[25]  G. Węgrzyn,et al.  Genistein Improves Neuropathology and Corrects Behaviour in a Mouse Model of Neurodegenerative Metabolic Disease , 2010, PloS one.

[26]  C. Kim,et al.  Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment , 2010, Genetics and molecular biology.

[27]  R. Wevers,et al.  Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations , 2010, Annals of neurology.

[28]  J. Hopwood,et al.  Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice , 2010, Experimental Neurology.

[29]  S. Dréano,et al.  A canine Arylsulfatase G (ARSG) mutation leading to a sulfatase deficiency is associated with neuronal ceroid lipofuscinosis , 2010, Proceedings of the National Academy of Sciences.

[30]  J. Esko,et al.  Loss of the Heparan Sulfate Sulfotransferase, Ndst1, in Mammary Epithelial Cells Selectively Blocks Lobuloalveolar Development in Mice , 2010, PloS one.

[31]  J. Hopwood,et al.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders , 2010, Journal of Inherited Metabolic Disease.

[32]  Joseph Zaia,et al.  Extended N-Sulfated Domains Reside at the Nonreducing End of Heparan Sulfate Chains* , 2010, The Journal of Biological Chemistry.

[33]  F. Wijburg,et al.  ‘Doctor Google’ ending the diagnostic odyssey in lysosomal storage disorders: parents using internet search engines as an efficient diagnostic strategy in rare diseases , 2010, Archives of Disease in Childhood.

[34]  B. Bigger,et al.  Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. , 2010, Molecular genetics and metabolism.

[35]  Shuji Mizumoto,et al.  Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence. , 2010, Glycobiology.

[36]  Yasuyuki Suzuki,et al.  Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I , 2010, Journal of Inherited Metabolic Disease.

[37]  Yasuyuki Suzuki,et al.  Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. , 2010, Molecular genetics and metabolism.

[38]  Yasuyuki Suzuki,et al.  Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography–tandem mass spectrometry , 2010, Journal of Inherited Metabolic Disease.

[39]  Richard D Cummings,et al.  Symbol nomenclature for glycan representation , 2009, Proteomics.

[40]  C. Götting,et al.  Quantitative determination and comparison of the glycosaminoglycan Δ‐disaccharide composition in 22 different human cell lines , 2009, Cell biology international.

[41]  David F. Smith,et al.  Glycan reductive isotope labeling for quantitative glycomics. , 2009, Analytical biochemistry.

[42]  B. Bigger,et al.  Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. , 2009, The Journal of pediatrics.

[43]  F. Cabré,et al.  Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. , 2009, International journal of clinical pharmacology and therapeutics.

[44]  D. Rapoport,et al.  Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I , 2009, Pediatrics.

[45]  R. Cummings,et al.  Evolutionary Differences in Glycosaminoglycan Fine Structure Detected by Quantitative Glycan Reductive Isotope Labeling* , 2008, Journal of Biological Chemistry.

[46]  P. Fernhoff,et al.  Heparin cofactor II-thrombin complex: a biomarker of MPS disease. , 2008, Molecular genetics and metabolism.

[47]  W. Sly,et al.  Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. , 2008, Molecular genetics and metabolism.

[48]  Roger Lawrence,et al.  Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans , 2008, Nature Methods.

[49]  J. Whitelock,et al.  Characterization and purification of glycosaminoglycans from crude biological samples. , 2008, Journal of agricultural and food chemistry.

[50]  S. Tomatsu,et al.  Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. , 2007, Analytical Biochemistry.

[51]  M. Mcentee,et al.  Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. , 2007, Molecular genetics and metabolism.

[52]  D. Tollefsen.  Heparin cofactor II modulates the response to vascular injury. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[53]  E. Wraith,et al.  Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease , 2007, Bone Marrow Transplantation.

[54]  D. Tollefsen,et al.  N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate. , 2006, Glycobiology.

[55]  C. Eng,et al.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.

[56]  G. Sinclair,et al.  Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. , 2006, Molecular genetics and metabolism.

[57]  J. Wittes,et al.  Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.

[58]  P. Savas,et al.  Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. , 2006, Molecular genetics and metabolism.

[59]  R. Giugliani,et al.  Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses , 2005, Journal of Inherited Metabolic Disease.

[60]  A. Ballabio,et al.  Sulfatases and human disease. , 2005, Annual review of genomics and human genetics.

[61]  J. Esko,et al.  The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.

[62]  T. Taketani,et al.  Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses , 2005, Journal of Inherited Metabolic Disease.

[63]  P. Meikle,et al.  Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases. , 2004, Molecular genetics and metabolism.

[64]  P. Meikle,et al.  Newborn Screening for Lysosomal Storage Disorders: Clinical Evaluation of a Two-Tier Strategy , 2004, Pediatrics.

[65]  P. Mabe,et al.  Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[66]  P. Meikle,et al.  Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. , 2004, Glycobiology.

[67]  T. Taketani,et al.  Development and Testing of New Screening Method for Keratan Sulfate in Mucopolysaccharidosis IVA , 2004, Pediatric Research.

[68]  P. Meikle,et al.  Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry. , 2003, Molecular genetics and metabolism.

[69]  Peter Finamore,et al.  A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). , 1999, Glycobiology.

[70]  J. Hopwood,et al.  Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. , 1998, Molecular genetics and metabolism.

[71]  M. Salmivirta,et al.  Differentiation-associated modulation of heparan sulfate structure and function in CaCo-2 colon carcinoma cells. , 1998, Glycobiology.

[72]  J. Esko,et al.  An Animal Cell Mutant Defective in Heparan Sulfate Hexuronic Acid 2-O-Sulfation* , 1996, The Journal of Biological Chemistry.

[73]  R. Wevers,et al.  Mucopolysaccharidoses Screening: Dimethylmethylene Blue versus Alcian Blue , 1994, Annals of clinical biochemistry.

[74]  U. Lindahl,et al.  Mode of interaction between platelet factor 4 and heparin. , 1993, Glycobiology.

[75]  H. Kleinman,et al.  High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). , 1991, The Journal of clinical investigation.

[76]  R. Wevers,et al.  Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. , 1989, Clinical chemistry.

[77]  J. Neglia,et al.  Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. , 1989, Clinical chemistry.

[78]  J. Hopwood,et al.  Urinary excretion of sulphated N-acetylhexosamines in patients with various mucopolysaccharidoses. , 1985, The Biochemical journal.

[79]  J. Hopwood,et al.  Isolation and characterization of N-acetylglucosamine 6-sulfate from the urine of a patient with Sanfilippo type D syndrome and its occurrence in normal urine. , 1983, Biochemistry International.

[80]  J. Hopwood,et al.  N-acetylglucosamine 6-sulfate residues in keratan sulfate and heparan sulfate are desulfated by the same enzyme. , 1983, Biochemistry International.

[81]  M. Innis.  Letter: Transmission of infectious mononucleosis by blood aerosol? , 1976, Lancet.

[82]  R. Giugliani,et al.  The mucopolysaccharidoses. , 1976, Journal of medical genetics.

[83]  P. Whiteman.  Prenatal diagnosis of mucopolysaccharidoses. , 1973, Lancet.

[84]  P. Meikle,et al.  Laronidase Treatment of Mucopolysaccharidosis I , 2012, BioDrugs.

[85]  F. Andrade,et al.  Reliability of a visual test for the rapid detection of mucopolysaccharidoses: GAG‐test® , 2011, Journal of clinical laboratory analysis.

[86]  S. Bloom.  Registries in chronic disease: coming your way soon? Registries--problems, solutions and the future. , 2011, Rheumatology.

[87]  P. Dickson.  Novel treatments and future perspectives: outcomes of intrathecal drug delivery. , 2009, International journal of clinical pharmacology and therapeutics.

[88]  E. Neufeld.  Enzyme replacement therapy – a brief history , 2006 .

[89]  Lin Shuan-Pei,et al.  MPS screening methods, the berry spot and acid turbidity tests, cause a high incidence of false‐negative results in sanfilippo and morquio syndromes , 2002, Journal of clinical laboratory analysis.

[90]  U Lindahl,et al.  Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. , 1994, The Journal of biological chemistry.

[91]  C. Cooney,et al.  Polysaccharide lyases , 1986, Applied biochemistry and biotechnology.